Same-day discovery of implantable cardioverter defibrillator dysfunction in the TRUST remote monitoring trial: influence of contrasting messaging systems

Niraj Varma, Behzad B Pavri, Bruce Stambler, Justin Michalski, TRUST Investigators, Niraj Varma, Behzad B Pavri, Bruce Stambler, Justin Michalski, TRUST Investigators

Abstract

Aims: Assess whether automatic remote home monitoring (HM) permits same-day evaluation of implantable cardioverter defibrillator (ICD) system dysfunction.

Methods and results: Compromised ICD system integrity (generator/lead) demands prompt evaluation. Home monitoring promises earlier discovery but may be limited by technological differences and follow-up mechanism. We tested whether HM enabled event review within 24 h, and contrasted differing messaging mechanisms. Nine hundred and eight patients in the TRUST prospective multicentre trial were followed by HM for 15 months. ICD system problems automatically triggered notifications: repeatedly ('redundant') for impedance deviations and elective replacement indication (ERI), but only a single transmission for '30 J ineffective'. Detection time from event onset to physician evaluation was measured. Forty-three system-related alerts occurred; 42% were asymptomatic, 42% were actionable, and 22 of 43 (51%) were viewed within 24 h. Redundant notifications were: 1 ERI, 9 shock impedance, 2 ventricular and 6 atrial pacing impedance. Most (11/18; 61%) were detected in <24 h. Others elicited daily notifications without interruption until resolution. For single transmissions, 11 of 25 (44%) events were detected on the same day. Most (56%, 14/25) were detected between 1 and 39 days (mean 10.0 ± 13.0 days). Ten of 14 events were detected by HM and 4 at the time of office visits. These observations suggest single transmissions were vulnerable to detection failure. Mean detection time of redundant events was 1.1 ± 1.8 vs. single transmission 5.6 ± 10.9 days (P = 0.05). Hence, redundant notification avoided late detection.

Conclusion: Same-day discovery of ICD dysfunction, even if asymptomatic, was achievable. For those events not evaluated within 24 h, repetitive messaging promoted earlier discovery. Reorganization of clinical follow-up methods may maintain early reaction ability.

Trial registration: ClinicalTrials.gov NCT00336284.

Figures

Figure 1
Figure 1
Events.
Figure 2
Figure 2
Days to detection of ICD problems in patients assigned to remote HM. Overall, 22 of 43 (51%) were detected within 24 h.
Figure 3
Figure 3
Example of redundant messaging following ventricular lead fracture in patient with ICD implanted for secondary prevention. Top event notification flagged (red exclamation mark on yellow background) for out of range ventricular lead impedance. The lead impedance trend (below) had been stable, (black dots) but then suddenly increased during sleep (2.52 am) promptly triggering an event notification (red dot on trend). The patient was unaware of this critical device integrity failure which occurred 7 days after a normal conventional check at an office visit (marked FU 8/28/2007). The patient was called immediately the same day (FU 9/5/2007), and lead replacement scheduled. System continued to transmit daily in the interim – a total of 8 redundant messages were sent until problem resolution, i.e. lead replacement and defibrillation threshold testing (marked VF event notification) with return of impedance to normal range (9/15/2007). With a conventional ICD, the issue may have remained unidentified until next device check 1 year later, putting patient at risk, but in this case automatic remote monitoring enabled same-day physician evaluation.
Figure 4
Figure 4
Summary data according to messaging method in patients assigned to remote HM. Days to the detection of ICD problems are contrasted between repeating (redundant) vs. single alerts. The majority (11/18) of redundant events were detected within 24 h (e.g. Figure 3). Single alerts were usually reviewed late.

References

    1. Carlson MD, Wilkoff BL, Maisel WH, Carlson MD, Ellenbogen KA, Saxon LA, et al. Recommendations from the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines Endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) and the International Coalition of Pacing and Electrophysiology Organizations (COPE) Heart Rhythm. 2006;3:1250–73.
    1. Maisel WH, Hauser RG, Hammill SC, Hauser RG, Ellenbogen KA, Epstein AE, et al. Recommendations from the Heart Rhythm Society Task Force on Lead Performance Policies and Guidelines: developed in collaboration with the American College of Cardiology (ACC) and the American Heart Association (AHA) Heart Rhythm. 2009;6:869–85.
    1. Varma N, Stambler B, Chun S. Detection of atrial fibrillation by implanted devices with wireless data transmission capability. Pacing Clin Electrophysiol. 2005;28(Suppl. 1):S133–6.
    1. Crossley GH, Chen J, Choucair W, Cohen TJ, Gohn DC, Johnson WB, et al. Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. J Am Coll Cardiol. 2009;54:2012–9.
    1. Crossley G, Boyle A, Vitense H, Chang Y, Mead RH. The clinical evaluation of remote notification to reduce time to clinical decision (CONNECT) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol. 2011;57:1181–9.
    1. Varma N. Rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) study. Am Heart J. 2007;154:1029–34.
    1. Varma N, Epstein A, Irimpen A, Schweikert R, Shah J, Love CJ Investigators. TRUST Investigators . Efficacy and safety of automatic remote monitoring for ICD Follow-Up: the TRUST trial. Circulation. 2010;122:325–32.
    1. Varma N. Remote monitoring for advisories: automatic early detection of silent lead failure. Pacing Clin Electrophysiol. 2009;32:525–7.
    1. Varma N, Epstein A, Irimpen A, Gibson L, Love CJ, Investigators T. Event notifications by remote monitoring systems performing automatic daily checks: load, characteristics and clinical utility. Eur Heart J. 2009;30:1909.
    1. Medtronic. 2007. Physician Advisory Letter: Urgent Medical Device Information Sprint Fidelis® Lead Patient Management Recommendations .
    1. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-Up (TRUST) trial. Circ Arrhythm Electrophysiol. 2010;3:428–36.
    1. Kallinen LM, Hauser RG, Lee KW, Almquist AK, Katsiyiannis WT, Tang CY, et al. Failure of impedance monitoring to prevent adverse clinical events caused by fracture of a recalled high-voltage implantable cardioverter-defibrillator lead. Heart Rhythm. 2008;5:775–9.
    1. Schoenfeld MH, Compton SJ, Mead RH, Weiss DN, Sherfesee L, Englund J, et al. Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. Pacing Clin Electrophysiol. 2004;27:757–63.
    1. Joseph GK, Wilkoff BL, Dresing T, Burkhardt J, Khaykin Y. Remote interrogation and monitoring of implantable cardioverter defibrillators. J Interv Card Electrophysiol. 2004;11:161–6.
    1. Zartner P, Handke R, Photiadis J, Brecher AM, Schneider MB. Performance of an autonomous telemonitoring system in children and young adults with congenital heart diseases. Pacing Clin Electrophysiol. 2008;31:1291–9.
    1. Neuzil P, Taborsky M, Holy F, Wallbrueck K. Early automatic remote detection of combined lead insulation defect and ICD damage. Europace. 2008;10:556–7.
    1. Spencker S, Coban N, Koch L, Schirdewan A, Muller D. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. Europace. 2009;11:483–8.
    1. Mabo P, Victor F, Bazin P, Ahres S, Babuty D, Da Costa A, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial) Eur Heart J. 2012;33:1105–1011.
    1. Perings C, Bauer WR, Bondke HJ, Mewis C, James M, Bocker D, et al. Remote monitoring of implantable-cardioverter defibrillators: results from the Reliability of IEGM Online Interpretation (RIONI) study. Europace. 2011;13:221–9.
    1. Hauser RG, Kallinen L. Deaths associated with implantable cardioverter defibrillator failure and deactivation reported in the United States Food and Drug Administration Manufacturer and User Facility Device Experience Database. Heart Rhythm. 2004;1:399–405.
    1. Varma N, Michalski J, Investigators T. Effect of transmission reliability on remote follow-up in ICD patients: automatic home monitoring in the TRUST trial. Heart Rhythm. 2012 9; issue 55, S164 (abstract)
    1. 2009. FDA A. Home Monitoring . P050023/S020.
    1. Cronin E, Ching EA, Varma N, Martin DO, Wilkoff B, Lindsay BD. Remote monitoring of cardiovascular devices- a time and activity analysis. Heart Rhythm. 2012 . [Epub ahead of print]
    1. Theuns DA, Rivero-Ayerza M, Knops P, Res JC, Jordaens L. Analysis of 57,148 transmissions by remote monitoring of implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009;32(Suppl. 1):S63–5.
    1. Mabo P, Defaye P, Sadoul N, Davy J, Deharo J, Kacet S. 2011. Remote follow-up of patients implanted with an ICD. The prospective randomized EVATEL study .
    1. Varma N, Johnson MA. Prevalence of cancelled shock therapy and relationship to shock delivery in recipients of implantable cardioverter-defibrillators assessed by remote monitoring. Pacing Clin Electrophysiol. 2009;32((Suppl. 1):S42–6.
    1. Kacet S. 2011. Safety and Effectiveness of ICD Follow-up using Remote Monitoring: ECOST Study. Presented in Hot Line Session at ESC 2011 Congress .
    1. Borleffs CJ, van Erven L, van Bommel RJ, van der Velde ET, van der Wall EE, Bax JJ, et al. Risk of failure of transvenous implantable cardioverter-defibrillator leads. Circ Arrhythm Electrophysiol. 2009;2:411–6.
    1. Ricci R, Morichelli L, D'Onofrio A, Zanotto G, Vaccari D, Calò L, et al. Home monitoring manpower, sensitivity and positive predictive value of adverse event detection. Preliminary results from the Home Guide registry. Eur Heart J. 2011;32(Suppl. 1):54.

Source: PubMed

3
Abonnieren